Pharmacological treatment of memory disorders caused by hypoxia and cerebral ischemia in rats

Author transcription pending · 1998 · Aviakosm Ekolog Med. 32(1):55–60

Animal / experimentalEnglish abstractSource linked

This is Molekul’s research summary, not the original publication. Educational information only, not medical advice. Seek qualified healthcare help for medical conditions.

What does this source report?

The indexed abstract identifies GVS-111 among nootropics investigated in hypoxia/ischemia-associated memory impairment.

Population and setting: Rat hypoxia / cerebral-ischemia memory models
Evidence type: Animal / experimental
Preparation: See the original report; formulation details require verification.
Source language: See original publication
Title provenance: Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.

What are the limitations?

Original results and compound-specific effects require full-paper extraction.
Not a human occupational trial.

Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.

Source access and review scope

Indexed primary abstract identified; full author list and methods remain pending.

Recorded source-check date: 2026-09-29. This date does not imply a completed systematic review.

Open original source or index record ↗

Cite and trace this record

Original source: Author transcription pending. Pharmacological treatment of memory disorders caused by hypoxia and cerebral ischemia in rats Aviakosm Ekolog Med. 32(1):55–60 1998.

Molekul research summary: https://molekul.io/research/noopept-hypoxia-1998. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.

Bibliography entry

Related compound profiles

Noopept

A defined synthetic dipeptide derivative connecting nootropic research with experimental environmental adaptation. Human chamber studies, clinical EEG reports and preclinical mechanisms address different questions; none establishes safe hazardous-work use.

Semax

ACTH-fragment-derived peptide with clinical stroke and optic-nerve reports, healthy-volunteer imaging and preclinical neuroregulation research. Precursor, patent and dissertation sources remain separately labeled.

Editorial policy and evidence standards